PUBLIC COMPANY
saveEXELIXIS
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of XB010 in Subjects With Solid Tumors
- phase3Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- phase3Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
- phase3Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
🐶 Hiring Signal
News
- Once undruggable, the Wnt/B-catenin pathway shows increasing promiseEarly-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types.biospace · 7d ago
- FDA extends review of Exelixis' colorectal cancer drug candidateCalifornia-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data led to a three-month exten…endpoints · 1mo ago
- FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerThe FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.fiercebiotech · 1mo ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 1mo ago
- Out of sight, out of work? What’s driving remote job cutsBiopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.biospace · 2mo ago
- Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think soWhen Exelixis CEO Michael Morrissey rolled out the biotech's final numbers for 2025 earlier in the year, there was no mistaking the outsized role that cabozantinib played in funding the company and…endpoints · 2mo ago
- After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…biospace · 2mo ago
comments(0)
5-min edit window · permanent after that